CLDN18.2靶向ADC 3期研究达到双主要终点;双靶点ADC 3期结果积极……

同花顺
Yesterday

CLDN18.2靶向ADC国际3期研究达到双主要终点,延长胃癌患者PFS和OS 武田(Takeda)和信达生物(HK1801)(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tavatecan治疗晚期胃癌的国际性3期G-HOPE-001研究结果。研究同时达到无进展生存期(PFS)和总生存期(OS)两项主要终点,显著延长既往接受过多线...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10